Cellceutix Corp. is a bio-pharmaceutical company focused on developing small molecule therapies in areas of unmet medical need, with a specific focus on cancer and inflammatory disease. The company has seven drugs targeting a number of human diseases.
What differentiates this company from others involved in cancer drug development is their lead product, Kevetrin. Cellceutix has demonstrated success in more than 5,000 small animal tests, proving significant delays in tumor growth compared to controls in breast, prostate and colon cancer tumors.
The senior management of Cellceutix is composed of people with long experience in researching, developing and marketing innovative pharmaceutical products. The officers and advisors of Cellceutix include pioneers in the fields of cancer and genetics, as well as people with wide experience in the pharmaceutical business.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment